Linical Company Limited and Alpha Cognition Inc. announced they have signed a partnering agreement whereby Linical will provide strategic consulting services and regulatory guidance for Alpha-1062, a new chemical entity aimed to penetrate the Alzheimer's disease market. Alpha-1062 is a patented new acetyl choline esterase inhibitor (AChEI) showing a significant reduction in side effects common in all other AChEI approved therapeutics. The product is being investigated in both an oral tablet and nasal spray delivery system. In placebo controlled Phase 1 and 1b human trials, the nasal formulation showed a decrease of over 90% in GI related adverse events compared to an approved AChEI at similar dose levels (Razadyn). Parallel development programs are ongoing with targeted approval in the United States in late 2022 or early 2023 with a subsequent approval in Japan. Regulatory guidance provided by the US FDA indicate that pivotal clinical trials can be initiated in late 2020. Similar meetings with Japan's PDMA were held earlier in 2020 and indicated a similar timeline. Linical, a mid-size contract research organization (CRO) working in CNS trials across the globe, will provide services to include: regulatory consulting, clinical trial support, post-marketing pharmacovigilance, medical information and safety support, as well as assisting with ACI's post-marketing phase IV programs. This development program will focus on the US and Japanese markets.